Increased proportions of Bifidobacterium and the Lactobacillus group and loss of butyrate-producing bacteria in inflammatory bowel disease

Journal of Clinical Microbiology

Volumn 52, Issue 2, 2014, Pages 398-406

  Wang, Wei ^a   Chen, Liping ^a   Zhou, Rui ^a,b   Wang, Xiaobing ^a   Song, Lu ^a   Huang, Sha ^a   Wang, Ge ^a   Xia, Bing ^a,b  

^a WUHAN UNIVERSITY   (China)

^b Hubei Cancer Clinical Study Center   (China)

Author keywords

[No Author keywords available]

Indexed keywords

RNA 16S;

ARTICLE; BACTERIUM; BACTERIUM IDENTIFICATION; BIFIDOBACTERIUM; BUTYRATE PRODUCING BACTERIA; CLOSTRIDIUM; CLOSTRIDIUM COCCOIDES; CLOSTRIDIUM LEPTUM; COLON BIOPSY; COLON MUCOSA; CONTROLLED STUDY; CROHN DISEASE; ESCHERICHIA COLI; FAECALIBACTERIUM PRAUSNITZII; FECES ANALYSIS; HOMEOSTASIS; HUMAN; HUMAN TISSUE; ILEUM MUCOSA; INFLAMMATORY BOWEL DISEASE; LACTOBACILLUS; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA GENE; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; BACTERIAL LOAD; BIFIDOBACTERIUM; BIOPSY; BIOTA; BUTYRATES; DYSBIOSIS; FECES; FEMALE; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; LACTOBACILLUS; MALE; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; RNA, BACTERIAL; RNA, RIBOSOMAL, 16S; YOUNG ADULT;

EID: 84893029775     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01500-13     Document Type: Article

References (48)

1. Chassaing B, Darfeuille-Michaud A. 2011. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140:1720-1728. http://dx.doi.org/10.1053/j.gastro.2011.01.054.
2. Sartor RB. 2006. Mechanisms of disease: pathogenesis of Crohn's disease and ulcerative colitis. Nature Clin. Pract. Gastroenterol. Hepatol. 3:390-407. http://dx.doi.org/10.1038/ncpgasthep0528.
3. Sartor RB. 2008. Microbial influences in inflammatory bowel diseases. Gastroenterology 134:577-594. http://dx.doi.org/10.1053/j.gastro.2007.11.059.
4. Neish AS. 2009. Microbes in gastrointestinal health and disease. Gastroenterology 136:65-80. http://dx.doi.org/10.1053/j.gastro.2008.10.080.
5. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. 2009. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am. J. Gastroenterol. 104:437-443. http://dx.doi.org/10.1038/ajg.2008.118.
6. Tursi A, Brandimarte G, Papa A, Giglio A, Elisei W, Giorgetti GM, Forti G, Morini S, Hassan C, Pistoia MA, Modeo ME, Rodino' S, D'Amico T, Sebkova L, Sacca' N, Di Giulio E, Luzza F, Imeneo M, Larussa T, Di Rosa S, Annese V, Danese S, Gasbarrini A. 2010. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am. J. Gastroenterol. 105:2218-2227. http://dx.doi.org/10.1038/ajg.2010.218.
7. Kruis W, Fric P, Pokrotnieks J, Lukás M, Fixa B, Kascák M, Kamm MA, Weismueller J, Beglinger C, Stolte M, Wolff C, Schulze J. 2004. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53:1617-1623. http://dx.doi.org/10.1136/gut.2003.037747.
8. Kato K, Mizuno S, Umesaki Y, Ishii Y, Sugitani M, Imaoka A, Otsuka M, Hasunuma O, Kurihara R, Iwasaki A, Arakawa Y. 2004. Randomized placebo-controlled trial assessing the effect of bifidobacteria-fermented milk on active ulcerative colitis. Aliment. Pharmacol. Ther. 20:1133-1141. http://dx.doi.org/10.1111/j.1365-2036.2004.02268.x.
9. Zocco MA, dal Verme LZ, Cremonini F, Piscaglia AC, Nista EC, Candelli M, Novi M, Rigante D, Cazzato IA, Ojetti V, Armuzzi A, Gasbarrini G, Gasbarrini A. 2006. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 23: 1567-1574. http://dx.doi.org/10.1111/j. 1365-2036.2006.02927.x.
10. Zakostelska Z, Kverka M, Klimesova K, Rossmann P, Mrazek J, Kopecny J, Hornova M, Srutkova D, Hudcovic T, Ridl J, Tlaskalova-Hogenova H. 2011. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLoS One 6:e27961. http://dx.doi.org/10.1371/journal.pone.0027961.
11. Patel RM, Myers LS, Kurundkar AR, Maheshwari A, Nusrat A, Lin PW. 2012. Probiotic bacteria induce maturation of intestinal claudin 3 expression and barrier function. Am. J. Pathol. 180:626-635. http://dx.doi.org/10.1016/j. ajpath.2011.10.025.
12. von Schillde MA, Hörmannsperger G, Weiher M, Alpert CA, Hahne H, Bäuerl C, van Huynegem K, Steidler L, Hrncir T, Pérez- Martínez G, Kuster B, Haller D. 2012. Lactocepin secreted by Lactobacillus exerts anti-inflammatory effects by selectively degrading proinflammatory chemokines. Cell Host Microbe 11:387-396. http://dx.doi.org/10. 1016/j.chom.2012.02.006.
13. Hoermannsperger G, Clavel T, Hoffmann M, Reiff C, Kelly D, Loh G, Blaut M, Hölzlwimmer G, Laschinger M, Haller D. 2009. Posttranslational inhibition of IP-10 secretion in IEC by probiotic bacteria: impact on chronic inflammation. PLoS One 4:e4365. http://dx.doi.org/10.1371/journal.pone.0004365.
14. Mohamadzadeh M, Pfeiler EA, Brown JB, Zadeh M, Gramarossa M, Managlia E, Bere P, Sarraj B, Khan MW, Pakanati KC, Ansari MJ, O'Flaherty S, Barrett T, Klaenhammer TR. 2011. Regulation of induced colonic inflammation by Lactobacillus acidophilus deficient in lipoteichoic acid. Proc. Natl. Acad. Sci. U. S. A. 108:4623-4630. http://dx.doi.org/10.1073/pnas.1005066107.
15. Schmidt EG, Claesson MH, Jensen SS, Ravn P, Kristensen NN. 2010. Antigen-presenting cells exposed to Lactobacillus acidophilus NCFM, Bifidobacterium bifidum BI-98, and BI-504 reduce regulatory T cell activity. Inflamm. Bowel Dis. 16:390-400. http://dx.doi.org/10.1002/ibd.21068.
16. Sokol H, Pigneur B, Watterlot L, Lakhdari O, Bermúdez- Humarán LG, Gratadoux JJ, Blugeon S, Bridonneau C, Furet JP, Corthier G, Grangette C, Vasquez N, Pochart P, Trugnan G, Thomas G, Blottière HM, Doré J, Marteau P, Seksik P, Langella P. 2008. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc. Natl. Acad. Sci. U. S. A. 105:16731-16736. http://dx.doi.org/10.1073/pnas.0804812105.
17. Scanlan PD, Shanahan F, O'Mahony C, Marchesi Jr. 2006. Cultureindependent analyses of temporal variation of the dominant fecal microbiota and targeted bacterial subgroups in Crohn's disease. J. Clin. Microbiol. 44:3980-3988. http://dx.doi.org/10.1128/JCM.00312-06.
18. Seksik P, Rigottier-Gois L, Gramet G, Sutren M, Pochart P, Marteau P, Jian R, Doré J. 2003. Alterations of the dominant faecal bacterial groups in patients with Crohn's disease of the colon. Gut 52:237-242. http://dx.doi.org/10.1136/gut.52.2.237.
19. Willing BP, Dicksved J, Halfvarson J, Andersson AF, Lucio M, Zheng Z, Järnerot G, Tysk C, Jansson JK, Engstrand L. 2010. A pyrosequencing study in twins shows that gastrointestinal microbial profiles vary with inflammatory bowel disease phenotypes. Gastroenterology 139:1844-1854. http://dx.doi.org/10. 1053/j.gastro.2010.08.049.
20. Sutherland LR, Martin F, Greer S, Robinson M, Greenberger N, Saibil F, Martin T, Sparr J, Prokipchuk E, Borgen L. 1987. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology 92:1894-1898.
21. Best WR, Becktel JM, Singleton JW, Kern F, Jr. 1976. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 70:439-444.
22. Willing B, Halfvarson J, Dicksved J, Rosenquist M, Järnerot G, Engstrand L, Tysk C, Jansson JK. 2009. Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn's disease. Inflamm. Bowel Dis. 15:653-660. http://dx.doi.org/10.1002/ibd.20783.
23. Round JL, Mazmanian SK. 2009. The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 9:313-323. http://dx.doi.org/10.1038/nri2515.
24. Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans AD, de Vos WM. 2002. Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl. Environ. Microbiol. 68:3401-3407. http://dx.doi.org/10.1128/AEM.68.7.3401-3407.2002.
25. Walter J, Hertel C, Tannock GW, Lis CM, Munro K, Hammes WP. 2001. Detection of Lactobacillus, Pediococcus, Leuconostoc, and Weissella species in human feces by using group-specific PCR primers and denaturing gradient gel electrophoresis. Appl. Environ. Microbiol. 67:2578-2585. http://dx.doi.org/10. 1128/AEM.67.6.2578-2585.2001.
26. Lepage P, Seksik P, Sutren M, de la Cochetière MF, Jian R, Marteau P, Doré J. 2005. Biodiversity of the mucosa-associated microbiota is stable along the distal digestive tract in healthy individuals and patients with IBD. Inflamm. Bowel Dis. 11:473-480. http://dx.doi.org/10.1097/01.MIB. 0000159662.62651.06.
27. Swidsinski A, Weber J, Loening-Baucke V, Hale LP, Lochs H. 2005. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J. Clin. Microbiol. 43:3380-3389. http://dx.doi.org/10.1128/JCM. 43.7.3380-3389.2005.
28. Walker AW, Sanderson JD, Churcher C, Parkes GC, Hudspith BN, Rayment N, Brostoff J, Parkhill J, Dougan G, Petrovska L. 2011. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and noninflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 11:7. http://dx.doi.org/10.1186/1471- 2180-11-7.
29. Kleessen B, Kroesen AJ, Buhr HJ, Blaut M. 2002. Mucosal and invading bacteria in patients with inflammatory bowel disease compared with controls. Scand. J. Gastroenterol. 37:1034-1041. http://dx.doi.org/10.1080/ 003655202320378220.
30. Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H. 2002. Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44-
31. http://dx.doi.org/10.1053/gast.2002.30294.
32. Mylonaki M, Rayment NB, Rampton DS, Hudspith BN, Brostoff J. 2005. Molecular characterization of rectal mucosa-associated bacterial flora in inflammatory bowel disease. Inflamm. Bowel Dis. 11:481-487. http://dx.doi.org/ 10.1097/01.MIB.0000159663.62651.4f.
33. Moran JP, Walter J, Tannock GW, Tonkonogy SL, Sartor RB. 2009. Bifidobacterium animalis causes extensive duodenitis and mild colonic inflammation in monoassociated interleukin-10-deficient mice. Inflamm. Bowel Dis. 15:1022-1031. http://dx.doi.org/10.1002/ibd.20900.
34. Medina M, Izquierdo E, Ennahar S, Sanz Y. 2007. Differential immunomodulatory properties of Bifidobacterium longum strains: relevance to probiotic selection and clinical applications. Clin. Exp. Immunol. 150: 531-538. http://dx.doi.org/10.1111/j.1365-2249.2007.03522.x.
35. Conte MP, Schippa S, Zamboni I, Penta M, Chiarini F, Seganti L, Osborn J, Falconieri P, Borrelli O, Cucchiara S. 2006. Gut-associated bacterial microbiota in paediatric patients with inflammatory bowel disease. Gut 55:1760-1767. http://dx.doi.org/10.1136/gut.2005.078824.
36. Jeon SG, Kayama H, Ueda Y, Takahashi T, Asahara T, Tsuji H, Tsuji NM, Kiyono H, Ma JS, Kusu T, Okumura R, Hara H, Yoshida H, Yamamoto M, Nomoto K, Takeda K. 2012. Probiotic Bifidobacterium breve induces IL-10-producing Tr1 cells in the colon. PLoS Pathog. 8:e1002714. http://dx.doi.org/10.1371/journal. ppat.1002714.
37. Goh YJ, Klaenhammer TR. 2009. Genomic features of Lactobacillus species. Front. Biosci. (Landmark Ed.) 14:1362-1386. http://dx.doi.org/10.2741/3313.
38. Mileti E, Matteoli G, Iliev ID, Rescigno M. 2009. Comparison of the immunomodulatory properties of three probiotic strains of lactobacilli using complex culture systems: prediction for in vivo efficacy. PLoS One 4:e7056. http://dx.doi.org/10.1371/journal.pone.0007056.
39. Matsuki T, Watanabe K, Fujimoto J, Miyamoto Y, Takada T, Matsumoto K, Oyaizu H, Tanaka R. 2002. Development of 16S rRNA-genetargeted group-specific primers for the detection and identification of predominant bacteria in human feces. Appl. Environ. Microbiol. 68: 5445-5451. http://dx.doi.org/10.1128/AEM. 68.11.5445-5451.2002.
40. Tsilingiri K, Barbosa T, Penna G, Caprioli F, Sonzogni A, Viale G, Rescigno M. 2012. Probiotic and postbiotic activity in health and disease: comparison on a novel polarised ex-vivo organ culture model. Gut 61: 1007-1015. http://dx.doi.org/10.1136/gutjnl-2011-300971.
41. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR. 2007. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. U. S. A. 104:13780-13785. http://dx.doi.org/10.1073/pnas.0706625104.
42. Martinez-Medina M, Aldeguer X, Gonzalez-Huix F, Acero D, Garcia-Gil LJ. 2006. Abnormal microbiota composition in the ileocolonic mucosa of Crohn's disease patients as revealed by polymerase chain reaction-denaturing gradient gel electrophoresis. Inflamm. Bowel Dis. 12: 1136-1145. http://dx.doi.org/10. 1097/01.mib.0000235828.09305.0c.
43. Klampfer L, Huang J, Sasazuki T, Shirasawa S, Augenlicht L. 2003. Inhibition of interferon gamma signaling by the short chain fatty acid butyrate. Mol. Cancer Res. 1:855-862.
44. Hansen R, Russell RK, Reiff C, Louis P, McIntosh F, Berry SH, Mukhopadhya I, Bisset WM, Barclay AR, Bishop J, Flynn DM, McGrogan P, Loganathan S, Mahdi G, Flint HJ, El-Omar EM, Hold GL. 2012. Microbiota of de-novo pediatric IBD: increased Faecalibacterium prausnitzii and reduced bacterial diversity in Crohn's but not in ulcerative colitis. Am. J. Gastroenterol. 107:1913-1922. http://dx.doi.org/10.1038/ajg.2012.335.
45. Ramirez-Farias C, Slezak K, Fuller Z, Duncan A, Holtrop G, Louis P. 2009. Effect of inulin on the human gut microbiota: stimulation of Bifidobacterium adolescentis and Faecalibacterium prausnitzii. Br. J. Nutr. 101:541-550. http://dx.doi.org/10.1017/S0007114508019880.
46. Ahmed S, Macfarlane GT, Fite A, McBain AJ, Gilbert P, Macfarlane S. 2007. Mucosa-associated bacterial diversity in relation to human terminal ileum and colonic biopsy samples. Appl. Environ. Microbiol. 73:7435-7442. http://dx.doi.org/10.1128/AEM.01143-07.
47. Santacruz A, Marcos A, Wärnberg J, Martí A, Martin-Matillas M, Campoy C, Moreno LA, Veiga O, Redondo-Figuero C, Garagorri JM, Azcona C, Delgado M, García-Fuentes M, Collado MC, Sanz Y, EVASYON Study Group. 2009. Interplay between weight loss and gut microbiota composition in overweight adolescents. Obesity (Silver Spring) 17:1906-1915. http://dx.doi.org/10.1038/ oby.2009.112.
48. Matsuki T, Watanabe K, Fujimoto J, Takada T, Tanaka R. 2004. Use of 16S rRNA gene-targeted group-specific primers for real-time PCR analysis of predominant bacteria in human feces. Appl. Environ. Microbiol. 70:7220-7228. http://dx.doi.org/10.1128/AEM.70.12.7220-7228.2004.